Recent Quotes (30 days)

You have no recent quotes
chg | %

Cynapsus Therapeutics Inc

(Inactive)  
Find more results for CTH

Address

828 Richmond St W
TORONTO, ON M6J 1C9
Canada
+1-416-7032449 (Phone)
+1-416-7038752 (Fax)
Cynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD). The Company completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a turning ON medication designed to convert a PD patient from the OFF to the ON state while avoiding the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes. Furthermore, the Company has initiated its pivotal Phase three clinical program for APL-130277.